CEDAX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CEDAX (CEDAX).
Ceftibuten is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP 3, thereby inhibiting peptidoglycan cross-linking and leading to cell lysis.
| Metabolism | Ceftibuten is not significantly metabolized; it is primarily eliminated unchanged in the urine via glomerular filtration and tubular secretion. No major hepatic metabolism. |
| Excretion | Renal: 92-96% unchanged; biliary/fecal: <5% |
| Half-life | Terminal elimination half-life: 2.6-3.0 hours; prolonged in renal impairment (up to 10-15 hours in severe impairment) |
| Protein binding | 85-90% bound to albumin |
| Volume of Distribution | 0.2-0.3 L/kg; indicates distribution primarily in extracellular fluid |
| Bioavailability | Oral: 85-90% |
| Onset of Action | Oral: within 1-2 hours; peak serum concentrations at 2-3 hours |
| Duration of Action | 12 hours; recommended twice-daily dosing for urinary tract infections |
| Molecular Weight | 479.6 |
400 mg orally once daily for 5-10 days.
| Dosage form | CAPSULE |
| Renal impairment | CrCl 30-49 mL/min: 200 mg every 24 hours; CrCl <30 mL/min (including hemodialysis): 200 mg every 48 hours. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment; not studied in severe impairment. |
| Pediatric use | Age 6 months to 12 years: 9 mg/kg (max 400 mg) orally once daily for 10 days. |
| Geriatric use | Use age-adjusted renal function for dosing; no specific dose adjustment beyond renal considerations. |
| 1st trimester | No adequate studies; use only if clearly needed. Animal studies show no evidence of harm. |
| 2nd trimester | Use with caution; limited human data but considered low risk. |
| 3rd trimester | Use with caution; potential for neonatal effects if used near term. |
Clinical note
Comprehensive clinical and safety monograph for CEDAX (CEDAX).
| Placental transfer | Crosses placenta; degree uncertain but likely low due to high protein binding. |
| Breastfeeding | Excreted into breast milk in small amounts; unlikely to cause adverse effects in infant. Consider risk-benefit. |
| Lactation Rating | L2 (Probably Compatible) |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to ceftibuten or other cephalosporins
| Precautions | Hypersensitivity reactions, including anaphylaxis, in patients with penicillin or other beta-lactam allergies, Clostridioides difficile-associated diarrhea (CDAD) ranging from mild diarrhea to fatal colitis, Renal impairment: dose adjustment required for creatinine clearance <50 mL/min, as accumulation may increase seizure risk, Superinfection with nonsusceptible organisms, particularly Enterococcus spp. and Candida albicans, during prolonged therapy |
| Food/Dietary | CEDAX should be taken with food to enhance oral absorption. No specific food restrictions, but avoid alcohol due to possible disulfiram-like reaction. |
Loading safety data…
| Teratogenic Risk | No evidence of teratogenicity in animal studies; insufficient human data. Avoid use in first trimester unless benefit outweighs risk; use caution in second and third trimesters. |
| Fetal Monitoring | Monitor for signs of hypersensitivity, diarrhea, and Clostridioides difficile infection in mother; fetal heart rate monitoring not specifically required. |
| Fertility Effects | No known significant effects on fertility based on animal studies and limited human data. |
| Clinical Pearls | CEDAX (cefditoren pivoxil) is a third-generation oral cephalosporin with enhanced activity against Gram-positive cocci including methicillin-susceptible Staphylococcus aureus and Streptococcus pneumoniae. It is prodrug requiring esterase hydrolysis; bioavailability increases with food. Not indicated for Pseudomonas or anaerobes. Do not use in patients with carnitine deficiency or those on valproic acid due to risk of valproate toxicity. |
| Patient Advice | Take with food to improve absorption and reduce GI upset. · Complete the full course even if symptoms improve. · Avoid alcohol during treatment and for 48 hours after to prevent disulfiram-like reaction. · Notify physician if rash, diarrhea, or unusual bleeding occurs. · Store at room temperature away from moisture. |